Skip to content
DataLookout
Menu

NCT07922798

A Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of UBT48128 Tablets in Healthy Participants

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Study completion pushed from Dec 30, 2026 to Mar 31, 2027
    • Start date: Nov 29, 2026 to Dec 1, 2026
    • Secondary endpoints: details revised at 1 of 9 entries
    • Study title shortened, about 3 words
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

incidence of adverse events (AEs), adverse drug reactions (ADRs), serious adverse events (SAEs), etc,..
Timeframe: Baseline to Day 6 and Day 13

Secondary (9)

Cmax
Tmax
AUC0-t
AUC0-∞
λz
Show 4 moreShow less
t1/2
CL/F
Vz/F
MRT

Arms and interventions

UBT48128Experimental

Ascending single doses - 6 dose levels

PlaceboPlacebo comparator

Ascending single doses - 6 dose levels

Drugs: UBT48128, Placebo

Sites

1 site in 1 country

  • The Second Xiangya Hospital of Central South UniversityChangsha, Hunan, China